Achilles Therapeutics (ACHL) Competitors $0.98 0.00 (0.00%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ACHL vs. ZURA, NKTX, CDTX, TCRX, VTYX, SCPH, NBTX, FTLF, MCRB, and ADAPShould you be buying Achilles Therapeutics stock or one of its competitors? The main competitors of Achilles Therapeutics include Zura Bio (ZURA), Nkarta (NKTX), Cidara Therapeutics (CDTX), TScan Therapeutics (TCRX), Ventyx Biosciences (VTYX), scPharmaceuticals (SCPH), Nanobiotix (NBTX), FitLife Brands (FTLF), Seres Therapeutics (MCRB), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "pharmaceutical products" industry. Achilles Therapeutics vs. Zura Bio Nkarta Cidara Therapeutics TScan Therapeutics Ventyx Biosciences scPharmaceuticals Nanobiotix FitLife Brands Seres Therapeutics Adaptimmune Therapeutics Achilles Therapeutics (NASDAQ:ACHL) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation, earnings and community ranking. Which has better earnings & valuation, ACHL or ZURA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchilles TherapeuticsN/AN/A-$69.67M-$1.65-0.59Zura BioN/AN/A-$69.24MN/AN/A Which has more volatility and risk, ACHL or ZURA? Achilles Therapeutics has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Zura Bio has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500. Is ACHL or ZURA more profitable? Zura Bio's return on equity of -37.36% beat Achilles Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Achilles TherapeuticsN/A -54.45% -47.68% Zura Bio N/A -37.36%-29.81% Does the media refer more to ACHL or ZURA? In the previous week, Zura Bio had 2 more articles in the media than Achilles Therapeutics. MarketBeat recorded 2 mentions for Zura Bio and 0 mentions for Achilles Therapeutics. Zura Bio's average media sentiment score of 0.74 beat Achilles Therapeutics' score of 0.00 indicating that Zura Bio is being referred to more favorably in the news media. Company Overall Sentiment Achilles Therapeutics Neutral Zura Bio Positive Do analysts prefer ACHL or ZURA? Achilles Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 308.16%. Zura Bio has a consensus price target of $15.80, suggesting a potential upside of 592.98%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts clearly believe Zura Bio is more favorable than Achilles Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achilles Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Zura Bio 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ACHL or ZURA? Zura Bio received 2 more outperform votes than Achilles Therapeutics when rated by MarketBeat users. Likewise, 82.61% of users gave Zura Bio an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote. CompanyUnderperformOutperformAchilles TherapeuticsOutperform Votes1754.84% Underperform Votes1445.16% Zura BioOutperform Votes1982.61% Underperform Votes417.39% Do insiders & institutionals believe in ACHL or ZURA? 56.4% of Achilles Therapeutics shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 5.4% of Achilles Therapeutics shares are held by insiders. Comparatively, 22.1% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryZura Bio beats Achilles Therapeutics on 13 of the 14 factors compared between the two stocks. Ad WealthPress70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << Get Achilles Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACHL vs. The Competition Export to ExcelMetricAchilles TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.28M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-0.5946.7391.3417.19Price / SalesN/A411.851,117.70116.80Price / CashN/A182.1042.6437.86Price / Book0.283.894.794.78Net Income-$69.67M-$42.21M$120.07M$225.60M7 Day Performance-1.00%-2.14%-1.90%-1.23%1 Month Performance-8.41%4.21%11.45%3.37%1 Year Performance18.02%18.40%30.63%16.58% Achilles Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACHLAchilles Therapeutics2.9925 of 5 stars$0.98flat$4.00+308.2%+18.1%$40.28MN/A-0.59250ZURAZura Bio3.2143 of 5 stars$2.51+10.1%$15.80+529.5%-52.8%$163.88MN/A0.003NKTXNkarta2.7945 of 5 stars$2.31-1.3%$15.00+549.4%-35.4%$163.01MN/A-1.24140Gap UpCDTXCidara Therapeutics3.6832 of 5 stars$23.00+0.5%$32.20+40.0%+54.8%$162.15M$63.90M-0.9090TCRXTScan Therapeutics2.1783 of 5 stars$3.00+5.3%$11.25+275.0%-38.6%$160.11M$21.05M-2.69100VTYXVentyx Biosciences2.9157 of 5 stars$2.26-0.9%$10.00+342.5%+7.7%$159.81MN/A-0.9773SCPHscPharmaceuticals3.2494 of 5 stars$3.18-0.3%$15.00+371.7%-43.6%$159.13M$13.59M-1.6830NBTXNanobiotix2.0847 of 5 stars$3.35+0.6%$12.00+258.2%-53.3%$157.90M$36.22M0.00100News CoverageGap UpFTLFFitLife Brands3.9627 of 5 stars$33.75-0.7%$40.00+18.5%+48.0%$155.18M$62.76M19.8220MCRBSeres Therapeutics3.3434 of 5 stars$0.89+1.3%$5.08+471.2%-14.4%$151.96M$126.33M-4.04233ADAPAdaptimmune Therapeutics1.9073 of 5 stars$0.59+1.7%$2.79+372.6%+37.1%$150.92M$60.28M-2.64449News Coverage Related Companies and Tools Related Companies ZURA Alternatives NKTX Alternatives CDTX Alternatives TCRX Alternatives VTYX Alternatives SCPH Alternatives NBTX Alternatives FTLF Alternatives MCRB Alternatives ADAP Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACHL) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achilles Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Achilles Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
